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valdecoxib), valdecoxib had a lower cost (€0.26) per
treatment day (95% CI: €-3.23, €2.72). The cost differ-
ence associated with GI-SAEs per treatment day was
lower for valdecoxib: €1.57 (95% CI; €3.90, €0.75).
CONCLUSIONS: Valdecoxib relative to diclofenac has
signiﬁcantly lower hospitalization costs per patient, and
the total costs for the two treatments are not signiﬁcantly
different, indicating that the superior safety beneﬁts with
valdecoxib might be achieved without an increase in total
treatment costs.
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OBJECTIVES: To evaluate the cost-effectiveness of etori-
coxib, a new selective Cox-2 inhibitor, in the treatment
of acute gouty arthritis compared with indomethacin in
the United Kingdom. METHODS: Using a recent clinical
trial comparing etoricoxib with indomethacin in the treat-
ment of acute gouty arthritis, a Markov model was built
based on four 8-day treatment cycles spread over four
years. In the trial, etoricoxib and indomethacin demon-
strated equivalent efﬁcacy but adverse event (AE) and
treatment discontinuation rates favored etoricoxib. In cal-
culating the total cost for each type of AE, its frequency
in the trial was taken into account. The medical treatment
of AEs and the average predicted probability of seeking
treatment were obtained from expert opinion and used
for the base case analysis. In the model, all patients suf-
fering an AE or discontinuing treatment selected a differ-
ent treatment for their next gout attack. The model
further assumed a general practitioner would treat all
patients and that an AE could necessitate one additional
GP visit. RESULTS: After one cycle of treatment the
incremental cost per patient successfully treated with
etoricoxib (no AE or discontinuation), including drug
therapy costs, was £15.43, decreasing to £6.27 over 4
cycles of treatment. CONCLUSION: In this study, etori-
coxib was a cost-effective alternative to indomethacin for
treatment of acute gouty arthritis based on the modelling
calculations using published clinical trial data and con-
servative assumptions regarding the treatment of AEs.
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OBJECTIVE: To determine the incremental cost-
effectiveness of COX-2-selective versus non-selective non-
steroidal anti-inﬂammatory drugs (NSAIDs) in relation 
to bleeding in a cohort of coumarin users. METHODS:
A pharmacoeconomic evaluation was linked to a case-
control design within an observational study in con-
comitant NSAID and coumarin users (with versus
without bleeding). Medical costs associated with bleeding
as well as costs associated with NSAID-use were deter-
mined, according to the Dutch guideline prices and
Health care tariffs. Rofecoxib, meloxicam, and nabume-
tone were considered to be COX-2-selective. Total costs
were calculated and compared for two hypothetical sce-
narios in which patients would use either COX-2-
selective NSAIDs or non-selective NSAIDs. Sensitivity
analyses were performed varying both the Odds Ratio
(OR) and costs of NSAIDs and bleedings. RESULTS:
A total of 1491 bleeding complications were detected
among 4400 coumarin users. Of the bleeders, 14.8% 
(n = 221) used a non-selective (96.1%) or COX-2-
selective (3.9%) NSAID. The OR for bleeding was 3.07
(95% CI 1.18–8.03) for non-selective versus COX-2-
selective NSAIDs. The mean cost of a bleeding was €478.
Factoring in the excess costs of COX-2-selective over
non-selective NSAID-use resulted in net savings of
€53,786. In the sensitivity analysis, cost savings remained,
except for situations with the OR in the lower range of
the conﬁdence interval (1.18–1.26). CONCLUSIONS: In
coumarin users, the reduction of bleeding complications
by the more expensive COX-2-selective inhibitors (com-
pared with non-selective NSAIDs) is also associated with
medical cost savings.
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OBJECTIVES: To assess the average prescribed daily
dose and cost of the two reimbursed coxibs, rofecoxib
and celecoxib, in Norway. Given the drugs’ different price
structures, prescribed number of tablets and strength
impact the daily treatment cost differentially. As a pre-
requisite for continued general reimbursement for rofe-
coxib and celecoxib from July 1, 2003, the Norwegian
Ministry of Health required post-marketing data regard-
ing prescription patterns in clinical practice to further
evaluate the drugs’ relative cost effectiveness. The Min-
istry’s re-evaluation will be based on this and other
studies. METHODS: All accessible physicians within the
ﬁeld of rheumatology (specialists) in Norway were invited
to prospectively register their prescriptions of reimbursed
coxibs for patients with Rheumatoid Arthritis (RA)
and/or Osteoarthritis (OA), over a period of 2 months
(October to December 2002). Data from registration
forms and patient records were collected through per-
